Yunnan Baiyao Group Co Ltd (SHE:000538) — Market Cap & Net Worth
Market Cap & Net Worth: Yunnan Baiyao Group Co Ltd (000538)
Yunnan Baiyao Group Co Ltd (SHE:000538) has a market capitalization of $13.25 Billion (CN¥90.53 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #1797 globally and #174 in its home market, demonstrating a 0.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yunnan Baiyao Group Co Ltd's stock price CN¥50.74 by its total outstanding shares 1784262603 (1.78 Billion). Also see 000538 current and non-current assets for a full breakdown of the balance sheet.
Yunnan Baiyao Group Co Ltd Market Cap History: 2015 to 2026
Yunnan Baiyao Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $10.66 Billion to $13.25 Billion (2.75% CAGR). Also see Yunnan Baiyao Group Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Yunnan Baiyao Group Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$3.97 Trillion | 0.33% | #64 of 285 |
Weight: Yunnan Baiyao Group Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Yunnan Baiyao Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yunnan Baiyao Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Yunnan Baiyao Group Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.39x
Yunnan Baiyao Group Co Ltd's market cap is 0.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.30x
Yunnan Baiyao Group Co Ltd's market cap is 3.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $10.66 Billion | $20.74 Billion | $2.77 Billion | 0.51x | 3.85x |
| 2016 | $11.29 Billion | $22.41 Billion | $2.92 Billion | 0.50x | 3.87x |
| 2017 | $15.22 Billion | $24.31 Billion | $3.14 Billion | 0.63x | 4.84x |
| 2018 | $11.23 Billion | $27.02 Billion | $3.49 Billion | 0.42x | 3.21x |
| 2019 | $13.93 Billion | $29.66 Billion | $4.18 Billion | 0.47x | 3.33x |
| 2020 | $18.30 Billion | $32.74 Billion | $5.52 Billion | 0.56x | 3.32x |
| 2021 | $17.39 Billion | $36.37 Billion | $2.80 Billion | 0.48x | 6.20x |
| 2022 | $13.03 Billion | $36.49 Billion | $3.00 Billion | 0.36x | 4.34x |
| 2023 | $12.10 Billion | $39.11 Billion | $4.09 Billion | 0.31x | 2.96x |
| 2024 | $15.65 Billion | $40.03 Billion | $4.75 Billion | 0.39x | 3.30x |
Competitor Companies of 000538 by Market Capitalization
Companies near Yunnan Baiyao Group Co Ltd in the global market cap rankings as of September 16, 2026. Review tangible net worth ratio of Yunnan Baiyao Group Co Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Yunnan Baiyao Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Yunnan Baiyao Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Yunnan Baiyao Group Co Ltd's market cap moved from $10.66 Billion to $ 13.25 Billion, with a yearly change of 2.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥13.25 Billion | -10.61% |
| 2025 | CN¥14.82 Billion | -5.32% |
| 2024 | CN¥15.65 Billion | +29.33% |
| 2023 | CN¥12.10 Billion | -7.11% |
| 2022 | CN¥13.03 Billion | -25.09% |
| 2021 | CN¥17.39 Billion | -4.97% |
| 2020 | CN¥18.30 Billion | +31.36% |
| 2019 | CN¥13.93 Billion | +24.10% |
| 2018 | CN¥11.23 Billion | -26.25% |
| 2017 | CN¥15.22 Billion | +34.87% |
| 2016 | CN¥11.29 Billion | +5.88% |
| 2015 | CN¥10.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Yunnan Baiyao Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.25 Billion USD |
| MoneyControl | $13.25 Billion USD |
| MarketWatch | $13.25 Billion USD |
| marketcap.company | $13.25 Billion USD |
| Reuters | $13.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yunnan Baiyao Group Co Ltd
Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China. The company offers health products; drugs; chemical raw materials, chemical preparations, sales of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, biological products, medical devices, health food, food, beverages, special labor protection products, production and sales … Read more